Objectives: The adverse sexual effects of androgen deprivation therapy (ADT) on men with prostate cancer have been well described. Less well known is the relative degree of sexual dysfunction and bother associated with ADT compared to other primary treatment modalities such as radical prostatectomy. We sought to describe the trajectory and relative magnitude of changes in sexual function and bother in men on ADT and to examine demographic and clinical predictors of ADT's adverse sexual effects.
The role of androgens in the pathophysiology of the disease has been well described. 2 The goal of androgen deprivation therapy (ADT) is to reduce levels of androgens, the hormones responsible for stimulating prostate cancer cells to grow. Androgen deprivation therapy is widely used as standard of care to treat non-metastatic and biochemically recurrent disease. 3 A recent study indicates that approximately 189 000 men with non-metastatic prostate cancer currently are being managed with ADT during the course of their disease. 4 Androgen deprivation therapy is not considered curative and is associated with a number of adverse effects. 5 Rates of erectile dysfunction with ADT are estimated between 70% and 90%. 3 In addition to erectile dysfunction, ADT also is associated with a number of other sexual effects. These include decreased sexual desire, inability to achieve orgasm, and decreased penile length and testicular size. 3, 5 Typically, the longer the duration of ADT, the more persistent the effects may be. 6 Whether men are highly bothered by the sexual effects of ADT in the context of a diagnosis of prostate cancer is not clear. Most studies have examined sexual bother in men treated with ADT in combination with radical prostatectomy (RP) or radiotherapy. [7] [8] [9] [10] In general, findings indicate a relative moderate effect of ADT on bother that stabilizes in the early period following initiation of treatment. In trying to account for this relative moderate effect, some have suggested that those treated with ADT understand that they have more severe disease and so may be more accepting of side effects. 3, 7 However, studies examining bother in men with prostate cancer on ADT as a primary treatment suggest an increase in bother over time. [11] [12] [13] Radical prostatectomy is a gold standard treatment for men diagnosed with localized prostate cancer. Erectile dysfunction is a common, well-known side effect of RP. A recent meta-analysis reported rates of erectile dysfunction after RP between 14% and 90%. 14 A number of prospective studies 8, [15] [16] [17] [18] [19] have described the course and magnitude of changes in erectile function after RP, demonstrating a decline in function in the initial postsurgical period with improvement over time. Approximately 1 of 5 men can be expected to return to baseline erectile function by 2 years after surgery. 20, 21 Other adverse sexual effects associated with RP include urinary incontinence and/or lack of ejaculate at orgasm, pain with orgasm, and changes in penile length and girth. 22, 23 Findings as to whether men are highly bothered by these RPrelated sexual effects in the context of a diagnosis of prostate cancer are mixed. 12, 24 Radical prostatectomy not only has the potential to cure prostate cancer but the adverse effects tend to diminish over time. Thus, men are likely to have relatively low levels of sexual bother in relation to these effects and/or to experience a degree of bother that improves over time as baseline levels of function are recovered. 23, 25, 26 Some have suggested, however, that men treated with RP do not adjust psychologically and that bother may be unrelated to sexual function and/or actually increase over time. 7, 23, 27 These mixed findings highlight the importance of distinguishing sexual function from bother in men with prostate cancer. 28 Different treatment modalities demonstrate distinctive patterns concerning sexual function over time. 7, 12 Whether these same modalities show characteristic or consistent patterns of bother and whether these patterns are more or less indicative of sexual function remain to be determined.
In the current study, we sought to describe the trajectory and relative magnitude of changes in both sexual function and bother in men with prostate cancer during a 1-year period after the initiation of ADT. We included 2 matched groups for comparison: men with prostate cancer treated with RP only and not receiving ADT and men with no history of cancer. We hypothesized that men in the ADT group would report worsening sexual function and increasing bother over time compared to the control groups. We also hypothesized that compared to men on ADT and men with no history of cancer, men treated with RP would demonstrate time-dependent improvements in sexual function and decreasing bother over time. ADT− group participants were matched to ADT+ group participants on time since diagnosis (within 6 mo); ADT− and CA− group participants were recruited to be matched to ADT+ participants on age (within 5 y) and educational level (12 y or less, 13-16 y, or 17 y or more). Baseline assessments were completed by ADT+ participants before or within 21 days of starting ADT and 6 and 12 months later. ADT− and CA− participants were assessed at similar time intervals.
| Measures
Age, marital status, education, race, and ethnicity were assessed at baseline via self-report. Medical comorbidities were assessed at baseline using a self-report version of the Charlson Comorbidity Index. 30 Gleason score was extracted via electronic medical record review.
Self-reported sexual functioning and bother from sexual functioning over the previous 4 weeks were assessed at each time point using the Sexual Function and Bother From Sexual Function scales of the Expanded Prostate Cancer Index Composite, 31 a valid and reliable measure that is widely used in studies of prostate cancer patients. 8 Scores on these scales range from 0 to 100, with higher scores indicating better quality of life (better function and less bother). In addition, Expanded Prostate Cancer Index Composite items asking about participants' level of sexual desire, ability to have an erection, and ability to reach climax were analyzed separately.
Scores on these items range from 1 to 5 with higher scores indicating better sexual function. was used as a cutoff for clinically significant differences from baseline to 12 months within the ADT+ group and between groups'
| Statistical analysis
12-month scores. Exploratory linear regression analyses were conducted using the PROCESS macro 36 to identify potential moderators of the effect of ADT on 12-month sexual function and bother while controlling for baseline values. For significant moderators, the Johnson-Neyman technique was used to calculate the region of significance: the value of the moderator above which ADT was no longer significantly associated with the outcome. 37 An α level of
.05 was used.
3 | RESULTS
| Demographic and clinical characteristics
Demographic and clinical characteristics for the sample* are shown in Significant group by time interactions were observed when comparing the ADT+ group to the ADT− and CA− groups on participants' level of sexual desire, ability to have an erection, and ability to climax (P values < .01; see Figure 2 ). The ADT+ group reported lower levels of sexual desire than the ADT− and CA− groups at each assessment (P values ≤ .05). The ADT+ and ADT− groups did not differ on ability to have an erection or ability to climax at baseline (P values ≥ .10), but the ADT+ group was less able to have an erection or climax than the ADT− group at 6 months (P values ≤ .04) and 12 months (P values ≤ .01). The ADT+ group was less able to have an erection or climax than the CA− group at all assessments (P values < .01). See Table 2 for effect sizes. Examinations of withingroup change over time indicated that while the ADT+ group worsened over time on levels of sexual desire, ability to have an erection, and ability to climax (P values < .01), the CA− group did not change over time on these outcomes (P values ≥ .06). The ADT− group did not change over time on levels of sexual desire (P = .62) but improved over time on ability to have an erection and ability to climax (P values < .01).
| Moderators of change in sexual function and bother
Exploratory analyses examined potential baseline moderators of the effect of ADT on sexual function and bother from sexual function.
Age moderated the effect of ADT on both sexual function and bother 
| DISCUSSION
The current study sought to describe the trajectory and relative magnitude of changes in sexual function and sexual bother in men with prostate cancer during a 1-year period after the initiation of ADT.
Results confirmed the hypothesis that prostate cancer patients receiving ADT would report worsening sexual function and increasing bother over time compared to prostate cancer patients who underwent RP only and were not receiving ADT and men with no history of cancer. Effect sizes for the differences in sexual function were large to very large while the differences in sexual bother ranged from small to very large. This pattern was also evident on single-item measures of sexual desire, ability to have an erection, and ability to reach climax with effect sizes ranging from medium to very large.
These findings build upon results from a study of 1269 men enrolled in the CaPSURE trial. 12 Among the 64 men who received ADT in that trial, sexual function worsened immediately after treatment with little or no recovery at year 1 after the initial decline. The increase in sexual bother in these men largely paralleled the course of sexual function, but to a lesser degree, and the investigators suggested this was evidence that patients seem to adjust to the changes. In the current study, bother increased significantly over time; at baseline and (5) 3 (3) Gleason score <.001 4-6 (low) 8 (13) 40 (47) 7 (intermediate) 22 (37) 39 (46) 8 (high) 19 (32) 2 (2) 9-10 (high) 7 (12) 0 (0) Missing 4 (6) 4 (5)
Abbreviations: ADT+, men with prostate cancer receiving androgen deprivation therapy; ADT−, men with prostate cancer not treated with androgen deprivation therapy; CA−, men with no cancer; SD, standard deviation.
Note: N = 232. P values calculated using χ 2 s for categorical variables and t-tests for continuous variables. Missing levels were excluded from calculation of P values.
6 months, there was no difference in sexual bother between men on ADT and men who underwent RP and were not on ADT. By 12 months, however, men on ADT reported significantly more bother than men who underwent RP only and non-cancer controls. We suggest this is evidence that men on ADT do not adjust to the changes and that sexual bother represents an important and relatively neglected target for intervention. However, definitive evidence for this can only come from studies with longer-term follow-up. 13 Certainly, the conflicting findings and conclusions to date highlight the need for additional research in this area.
Our findings also confirmed the hypothesis that prostate cancer patients treated with RP only who were not receiving ADT would report improvement over time in sexual function. Both erectile function and ability to climax improved over time. Consistent with previous studies demonstrating that sexual desire is relatively preserved after RP, 23 level of desire did not change over the course of the study but remained similar to that of men with no history of cancer and significantly higher than that reported by men on ADT. With respect to sexual bother, as hypothesized, RP patients' bother decreased over time in a pattern that mirrored the improvement over time in sexual function. This pattern of results is consistent with the results of the CaPSURE trial referenced previously. 12 The men who underwent RP Results of the exploratory analyses indicated that age moderated the effect of ADT on both sexual function and bother. Younger age predicted relatively poorer sexual function and greater bother at 12 months in men on ADT compared to men not on ADT. This was not the case in older men. Older men on ADT did not report significantly worse sexual function or more bother than older men who were not on ADT. These findings are consistent with a large retrospective review of CaPSURE registry data investigating the effect of age on prostate cancer outcomes that found that treatments have an effect on outcomes depending on age and whether the treatment is local (as in RP or radiation) or nonlocal (as in ADT or surveillance). 38 In that study, men <60 years of age were more likely to report greater declines and better recovery in sexual function as well as worse sexual bother over time compared to men >70 years of age. Analyses of the effect of treatment showed that rates of sexual dysfunction were treatment-dependent for men <60 years but similar across treatments for men >70 years of age while sexual bother worsened after local treatment both for men <60 years and men >70 years. Similarly, a recent cross-sectional study found that while most men on ADT for metastatic prostate cancer experienced a decline in sexual function, there was variability in the men's degree of bother, with younger men reporting higher levels of sexual bother. 9 These recent findings as well as our own underscore the clinical relevance of bother and the need for interventions that target sexual bother, whether or not such interventions include medical therapies aimed at improving sexual function. When sexual function is not expected to improve, as is the case for most men on ADT, sexual bother is likely to be a more meaningful indicator of a man's psychological adjustment to the effects of ADT.
| Limitations
Limitations of the study should be noted. First, patients in the current study were followed for only 12 months following the initiation of 
| Clinical implications
Sexual function is a widely assessed and important patient-reported 
